<p>Ligand Pharmaceuticals（纳斯达克股票代码：LGND）在过去三个月内被 4 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
<p>下表提供了他们最近评级的快速概述，突出了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 182.0 美元，最高预估为 206.00 美元，最低预估为 162.00 美元。当前平均价格目标超过之前的 154.25 美元，增加了 17.99%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png"/></p>
<h2>理解分析师评级：全面解析</h2>
<p>通过审查近期分析师的行动，我们可以深入了解金融专家如何看待 Ligand Pharmaceuticals。以下总结概述了主要分析师、他们的近期评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>上调</td>
<td>买入</td>
<td>175.00 美元</td>
<td>160.00 美元</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上调</td>
<td>买入</td>
<td>206.00 美元</td>
<td>157.00 美元</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越市场</td>
<td>185.00 美元</td>
<td>155.00 美元</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超越市场</td>
<td>162.00 美元</td>
<td>145.00 美元</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对 Ligand Pharmaceuticals 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “超越市场” 到 “表现不佳”。这些评级反映了对 Ligand Pharmaceuticals 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师评估价格目标的动态，提供对 Ligand Pharmaceuticals 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>将这些分析师评估与相关财务指标结合分析，可以提供对 Ligand Pharmaceuticals 市场地位的全面视角。保持信息灵通，并借助我们的评级表做出数据驱动的决策。</p>
<p>随时了解 Ligand Pharmaceuticals 的分析师评级。</p>
<h2>发现 Ligand Pharmaceuticals：更深入的了解</h2>
<p>Ligand Pharmaceuticals Inc 是一家生物制药公司，专注于开发和获取有助于药物创造的技术。该公司与多家制药和生物技术公司建立了合作关系和许可协议。Ligand 的商业模式基于药物发现、早期药物开发、产品改良和合作。公司的收入主要由三个部分组成：来自商业化产品的特许权使用费、许可和里程碑付款，以及其商标 Captisol 材料的销售。</p>
<h3>关键指标：Ligand Pharmaceuticals 的财务健康状况</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模限制。这可能受到增长预期或运营能力等因素的影响。</p>
<p><strong>积极的收入趋势：</strong> 对 Ligand Pharmaceuticals 的财务状况进行 3 个月的审查显示出积极的叙述。截止 2025 年 6 月 30 日，该公司实现了显著的收入增长率，达到了 <strong>14.68%</strong>，显示出顶线收益的显著增加。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Ligand Pharmaceuticals 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>10.18%</strong>，展现出强大的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> 公司的 ROE 表现突出，超过行业平均水平。ROE 达到 <strong>0.6%</strong>，展示了对股本资本的有效利用。</p>
<p><strong>资产回报率（ROA）：</strong> Ligand Pharmaceuticals 的 ROA 表现突出，超过行业平均水平。ROA 达到 <strong>0.52%</strong>，展示了对资产的有效利用和强劲的财务表现。</p>
<p><strong>债务管理：</strong> 该公司保持了平衡的债务管理，债务与股本比率低于行业标准，达到 <strong>0.01</strong>。</p>
<h2>分析师评级的基础知识</h2>
<p>分析师在银行和金融系统中工作，通常专注于股票或特定行业的报告。分析师可能会参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度对每只股票进行一次评级。</p>
<p>分析师可能通过纳入增长预期、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
<p><strong>目前分析师推荐哪些股票？</strong></p>
<p>Benzinga Edge 让您即时获取所有主要分析师的评级上调、下调和价格目标。可以按准确性、上涨潜力等进行排序。点击这里以领先市场。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

Ligand制药

<p>Ligand Pharmaceuticals（纳斯达克代码：LGND）在过去三个月内获得了 4 位分析师的混合评级，12 个月的平均目标价为 182.00 美元，比之前的目标上涨了 17.99%。最近的升级包括 Benchmark 和 HC Wainwright 给予的 “买入” 评级，目标价分别提高至 175.00 美元和 206.00 美元。该公司展现出强劲的财务健康状况，净利润率为 10.18%，股本回报率为 0.6%。分析师的评估反映了他们对市场动态和公司表现的回应，为 Ligand 的市场地位提供了洞察</p>

<p>Ligand Pharmaceuticals (NASDAQ: LGND) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals（纳斯达克股票代码：LGND）在过去三个月内被 4 位分析师分析，显示出从看涨到看跌的多样化观点。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快速概述，突出了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $182.0, with a high estimate of $206.00 and a low estimate of $162.00. Surpassing the previous average price target of $154.25, the current average has increased by 17.99%.</p>
<div class="lb-trans"><p>分析师对 12 个月价格目标的评估提供了额外的见解，显示出平均目标为 182.0 美元，最高预估为 206.00 美元，最低预估为 162.00 美元。当前平均价格目标超过之前的 154.25 美元，增加了 17.99%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2025/1756850481_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析师评级：全面解析</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Ligand Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审查近期分析师的行动，我们可以深入了解金融专家如何看待 Ligand Pharmaceuticals。以下总结概述了主要分析师、他们的近期评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$206.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>上调</td>
<td>买入</td>
<td>175.00 美元</td>
<td>160.00 美元</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上调</td>
<td>买入</td>
<td>206.00 美元</td>
<td>157.00 美元</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越市场</td>
<td>185.00 美元</td>
<td>155.00 美元</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>上调</td>
<td>超越市场</td>
<td>162.00 美元</td>
<td>145.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ligand Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ligand Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对 Ligand Pharmaceuticals 近期发展的反应。这为分析师对公司当前状态的看法提供了见解。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “超越市场” 到 “表现不佳”。这些评级反映了对 Ligand Pharmaceuticals 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师评估价格目标的动态，提供对 Ligand Pharmaceuticals 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ligand Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与相关财务指标结合分析，可以提供对 Ligand Pharmaceuticals 市场地位的全面视角。保持信息灵通，并借助我们的评级表做出数据驱动的决策。</p>
</div><p>Stay up to date on Ligand Pharmaceuticals analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Ligand Pharmaceuticals 的分析师评级。</p>
</div><h2>Discovering Ligand Pharmaceuticals: A Closer Look</h2>
<div class="lb-trans"><h2>发现 Ligand Pharmaceuticals：更深入的了解</h2>
</div><p>Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Inc 是一家生物制药公司，专注于开发和获取有助于药物创造的技术。该公司与多家制药和生物技术公司建立了合作关系和许可协议。Ligand 的商业模式基于药物发现、早期药物开发、产品改良和合作。公司的收入主要由三个部分组成：来自商业化产品的特许权使用费、许可和里程碑付款，以及其商标 Captisol 材料的销售。</p>
</div><h3>Key Indicators: Ligand Pharmaceuticals's Financial Health</h3>
<div class="lb-trans"><h3>关键指标：Ligand Pharmaceuticals 的财务健康状况</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模限制。这可能受到增长预期或运营能力等因素的影响。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining Ligand Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>14.68%</strong> as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>积极的收入趋势：</strong> 对 Ligand Pharmaceuticals 的财务状况进行 3 个月的审查显示出积极的叙述。截止 2025 年 6 月 30 日，该公司实现了显著的收入增长率，达到了 <strong>14.68%</strong>，显示出顶线收益的显著增加。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Ligand Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.18%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Ligand Pharmaceuticals 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>10.18%</strong>，展现出强大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.6%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 公司的 ROE 表现突出，超过行业平均水平。ROE 达到 <strong>0.6%</strong>，展示了对股本资本的有效利用。</p>
</div><p><strong>Return on Assets (ROA):</strong> Ligand Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.52%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Ligand Pharmaceuticals 的 ROA 表现突出，超过行业平均水平。ROA 达到 <strong>0.52%</strong>，展示了对资产的有效利用和强劲的财务表现。</p>
</div><p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 该公司保持了平衡的债务管理，债务与股本比率低于行业标准，达到 <strong>0.01</strong>。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析师评级的基础知识</h2>
</div><p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically rate each stock once per quarter.</p>
<div class="lb-trans"><p>分析师在银行和金融系统中工作，通常专注于股票或特定行业的报告。分析师可能会参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 “分析师评级”。分析师通常每季度对每只股票进行一次评级。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析师可能通过纳入增长预期、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
</div><p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<div class="lb-trans"><p><strong>目前分析师推荐哪些股票？</strong></p>
</div><p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.</p>
<div class="lb-trans"><p>Benzinga Edge 让您即时获取所有主要分析师的评级上调、下调和价格目标。可以按准确性、上涨潜力等进行排序。点击这里以领先市场。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

分析师们对 Ligand 制药股票的评价